This study describes the number and type of clinical offices receiving detailing visits and free drug samples from pharmaceutical companies.
This nationwide survey of US primary care internists and medical specialists evaluates physicians’ attitudes about the US Food and Drug Administration’s drug approval standards and off-label drug marketing.
This cohort study examines the trend in prescription testosterone use among male Medicare beneficiaries with and without coronary artery disease aged 50 years or older.
In this study, Schwartz and Woloshin estimate that spending on marketing of prescription drugs, disease awareness, and health and laboratory services in the US increased from $17.7 to $29.9 billion between 1997 and 2016, with the most rapid increase in direct-to-consumer (DTC) advertising of drugs (mainly high-cost biologics and cancer immunotherapy) and disease awareness campaigns.
This Viewpoint examines the cost and efficacy of Restasis (cyclosporine ophthalmic emulsion, 0.05%) for the treatment of dry eye disease.
This study describes the number of interim reports of ongoing randomized trials published between 2006 and 2015, the reasons for interim reporting, and differences in the abstract conclusions between interim and final publications.
This survey study examines how well physicians understand the US Food and Drug Administration’s (FDA’s) statutory definition of a “breakthrough” therapy, and whether the term breakthrough affects their perceptions of a drug’s efficacy.
This randomized trial explores why press releases with neutral terms—and that routinely explain the limited evidence supporting accelerating approval—might help consumers make more accurate judgments about drugs with “breakthrough” designation.
Wiener et al characterize pulmonary nodule evaluation and concordance with the Fleischner Society guidelines for management.
Woloshin and Schwartz highlight the possible adverse effects of lorcaserin and phentermine-topiramate.
You currently have no searches saved.
Create a personal account or sign in to: